12:04 PM EST - Optimi Health : Announced that it has entered into a supply agreement with Halucenex Life Sciences Inc., a wholly owned subsidiary of Creso Pharma of Australia. Halucenex is based in Windsor, Nova Scotia and is a life sciences company focused on researching novel psychedelic compounds, developing and licensing psychedelic compounds for the pharmaceutical and nutraceutical markets, and conducting clinical trials on the medical benefits of psychedelic medicine. Optimi Health
shares C.OPTI are trading up $0.03 at $0.26.
